RNA-binding protein multimerization inhibitors and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12435091-B2
Application number	US-202117996886-A
Country	US
Kind code	B2
Filing date	Apr 21, 2021
Priority date	Apr 21, 2020
Publication date	Oct 7, 2025
Grant date	Oct 7, 2025

Abstract

This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.

First claim

What is claimed is:

1. A compound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof, wherein:
is a single bond or a double bond;
R 1 , R 2 , and R 3 are each independently selected from the group consisting of hydrogen, halogen, cyano, trifluoromethyl, alkoxy, aryloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl;
X is NR 4 R 5 or OR 4 , wherein R 4 and R 5 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl;
Y 1 , Y 2 , and Y 3 are each independently selected from NR 6 and CR 7 , wherein R 6 and R 7 are each independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbonyl,
wherein at least two of Y 1 , Y 2 , and Y 3 are N, and wherein the compound is not:

2. The compound of claim 1 , wherein the compound has the following formula:

3. The compound of claim 2 , wherein R 4 is hydrogen, or wherein R 5 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted alkyl, or wherein R 6 is hydrogen or C 1 -C 6 alkyl, or wherein R 7 is hydrogen, C 1 -C 6 alkyl, or acetyl.

4. The compound of claim 1 , wherein the compound has the following formula:

5. The compound of claim 4 , wherein the compound is selected from the group consisting of:

6. The compound of claim 4 , wherein R 4 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted alkyl, or wherein R 6 is hydrogen or C 1 -C 6 alkyl, or wherein R 7 is hydrogen, C 1 -C 6 alkyl, or acetyl, or wherein R 1 , R 2 and R 3 are H.

7. The compound of claim 1 , wherein the compound is selected from the group consisting of:

8. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

9. A method of treating cancer in a subject, comprising:
administering to a subject an effective amount of a compound of claim 1 .

10. The method of claim 9 , wherein the cancer is a brain cancer.

11. The method of claim 9 , wherein the cancer is glioma.

12. The method of claim 9 , further comprising administering to the subject a second therapeutic agent.

13. The method of claim 12 , wherein the second therapeutic agent comprises a chemotherapeutic agent.

14. The method of claim 9 , wherein the compound is selected from the group consisting of:

15. A method of treating inflammation in a subject, comprising:
administering to a subject an effective amount of a compound of claim 1 .

16. The method of claim 15 , wherein the compound is selected from the group consisting of:

17. A method of treating neuropathic pain in a subject comprising:
administering to a subject an effective amount of a compound of claim 1 .

18. The method of claim 17 , wherein the compound is selected from the group consisting of:

19. A method of inhibiting HuR multimerization in a cell, comprising:
contacting a cell with an effective amount of a compound of claim 1 .

20. A method of treating a central nervous system (CNS) injury in a subject, comprising:
administering to a subject an effective amount of a compound of claim 1 .

21. The method of claim 20 , wherein the CNS injury is selected from the group consisting of stroke, traumatic brain injury and spinal cord injury.

22. The method of claim 21 , wherein the stroke is an ischemic or hemorragic stroke.

Assignees

• Uab Res Found
• Southern Res Inst
• Us Gov Veterans Affairs
• The Us Gov As Represented By The Department Of Veteran Affairs

Inventors

• Nabors Louis B
• Filippova Natalia
• Yang Xiuhua
• Ananthan Subramaniam
• Pathak Vibha
• King Peter

Classifications

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title